| |
NGS is unlocking new possibilities in discovery and diagnostics, but few solutions can keep up with its needs. Access our toolkit to discover how out-of-the-box NGS empowers innovators to hit the ground running. Learn more.
|
|
Today's Big NewsJul 10, 2023 |
|
Sciensus offers the infrastructure, regulatory expertise and experience to navigate the complexities of international distribution and get your rare drugs to hard-to-reach patients. Learn more.
|
|
| By Angus Liu After a major phase 2 win that stirred up much excitement within the oncology community, Merck has officially formulated a pivotal trial plan for its Moderna-partnered mRNA cancer vaccine mRNA-4157. |
|
|
|
By Nick Paul Taylor Johnson & Johnson has seized on the cash crunch at Nanobiotix to pick up a phase 3 cancer prospect for $30 million upfront. The deal gives J&J global rights to a candidate, NBTXR3, that is designed to enhance the efficacy of radiotherapy to improve outcomes in tumor types including head and neck cancer. |
By Nick Paul Taylor Duality Biologics has caught the eye of another global biotech. Months after inking a deal with BioNTech, the antibody-drug conjugate (ADC) specialist has granted BeiGene an option on a preclinical asset in return for a financial package worth up to $1.3 billion. |
Sponsored by Clinical Enrollment Using behavioral data science and social algorithms, this boutique biotech agency creates therapeutic-specific and patient-centric content to bypass traditional channels and speak directly to patients. |
By Gabrielle Masson The icy IPO market for biotech may be thawing slightly, with two companies—Apogee Therapeutics and Sagimet Biosciences—revealing their pricing plans for going public. |
Sponsored by OneStudyTeam Hear why sponsors should equip sites with technology that makes securely capturing pre-screening, recruitment, and enrollment data easier. |
By James Waldron Earlier this year, GSK executives explained to Fierce Biotech why they felt the company’s push into oligonucleotides was such a good fit. Now, the British Big Pharma has added further depth to this strategy courtesy of a research collaboration with Elsie Biotechnologies. |
By James Waldron In the wake of Nymox Pharmaceutical’s shares being kicked off the Nasdaq, the embattled biotech is now facing a mutiny led by former executives unhappy that the company turned down a deal with AscellaHealth. |
By Annalee Armstrong Iovance Biotherapeutics has never taken a straight path from A to B when it comes to developing its tumor-infiltrating lymphocyte therapies. But this time, the California biotech seems to have found a solution that could mean an accelerated nod for a lung cancer medicine. |
By Helen Floersh Findings from the largest-ever atlas of cells in healthy human breasts shows how even with decades of research, there's still so much more to learn. |
By Kevin Dunleavy Two cases of suicidal thoughts and one case of self-harm from users in Iceland of Novo Nordisk’s diabetes and obesity drugs have prompted the European Medicines Agency (EMA) to review the blockbuster products. The regulator will examine Novo’s treatments Ozempic and Saxenda to determine if there was a causal relationship between their use and the adverse events. |
By Conor Hale The diagnostics company Quanterix hopes to gain new ground following the FDA’s recent full approval of Eisai and Biogen’s Leqembi treatment for Alzheimer’s disease, with the launch of an ultrasensitive blood test and a storefront for healthcare providers. |
By Angus Liu Canada has canceled some COVID-19 vaccine deliveries from Novavax and will pay $350 million to fully compensate the company for those unused doses. The survival of the Maryland-based company now depends on the successful delivery of an updated COVID shot this fall. |
By Andrea Park After experiencing a boom in 2021 to make up for the dearth of dealmaking in 2020, M&A moves and VC fundraising in the medtech industry have been on a steady downward slope. |
By Frank Diamond Though experts agree that maternal mortality ratios contribute to the problem of racial and ethnic healthcare disparities, a study in JAMA Network notes that a lack of a universal method for reporting maternal deaths makes it difficult to pinpoint the scope of the problem. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines. |
|
|---|
|
|
| ResearchThe right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
